Capricor Therapeutics is trading 5.22% lower at $7.08, with no confirmed company announcement explaining the decline on October 13. - The biotech sector is also lower, with XBI down 2.01% during the regular session; available evidence does not establish it as the sole cause. - HOPE-3 extension data reported October 5 and investor concerns about FDA approval predate this session and do not establish a fresh catalyst.